Wikisage, the free encyclopedia of the second generation, is digital heritage
Perampanel: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
mNo edit summary |
||
| Line 14: | Line 14: | ||
[http://onlinelibrary.wiley.com/doi/10.1111/epi.12212/full Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies] | [http://onlinelibrary.wiley.com/doi/10.1111/epi.12212/full Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies] | ||
{{wikidata|Q868658}} | |||
<references/> | <references/> | ||
[[Category:Anticonvulsant]] | [[Category:Anticonvulsant]] | ||
Revision as of 19:21, 10 January 2018
(Fycompa) is an AED [1] 5′-(2-Cyanphenyl)-1′-phenyl-2,3′-bipyridinyl-6′(1′H)-on
[2] Perampanel was efficacious and well tolerated, despite the observation that the patient population exhibited characteristics of highly refractory epilepsy
